23andMe Investor Presentation Deck

23andMe Therapeutics IO Pipeline: First-in-Class Potential 23ME'610 anti-CD200R1 23ME'1473 anti-ULBP6 Target Discovery ● Lead Optimization Solid tumors, clinical stage, 10 effectorless mAb Solid tumors, IO effector-enhanced mAb 23ME'610/anti-CD200R1 Targets Innate and Adaptive Immunity Potent Ab with great PK/PD • Phase 1 monotx with on-target AEs • Ph2a data expected to be presented mid- 2024 Note: '610 is in Phase 1/2a as of January 2024. IND Enabling Phase 1 Phase 2 Phase 2a* 23ME'1473/anti-ULBP6 • Activator of tumor NK cells • Effector-enhanced Ab with dual NK- activating MOA Copyright © 2024 23and Me, Inc. 23and Me 21

View entire presentation